Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Addict Neurosci. 2023 May 18;7:100103. doi: 10.1016/j.addicn.2023.100103

Table 2.

Novel compounds in clinical testing for smoking cessation.

Compound Mechanism of Action Sponsor Status Phase
Suvorexant Hcrt1/2 receptor antagonist University of Texas Health Science Center Recruiting Phase 1
Baclofen GABAB receptor agonist University of Pennsylvania Completed Phase 2
Naltrexone MOR antagonist University of Chicago Completed Phase 2
Naltrexone combined with Bupropion MOR antagonist and antidepressant Yale University Completed Phase 2
Selegiline MAO-B Inhibitor NIDA Completed Phase 2
AZD8529 mGluR2 PAM NIDA Completed Phase 2
Gemfibrozil PPARα agonist University of Texas Completed Phase 2
S-adenosyl-L-Methionine (SAMe) Facilitates monoamine synthesis Mayo Clinic Completed Phase 2/3